Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Roche Pushes The Boundaries Of Cancer Immunotherapy

Jun 09 2017

• By Bridget Silverman

3d illustration of T cells or cancer cells

Related Content

Roche Sees Biomarker-Guided Discovery As Key To Unlocking Tumor Microenvironment

Jun 18 2014

INTERVIEW: Roche's Dan Chen Talks Immuno-Oncology Combinations

Jun 24 2016

For Roche Immuno-Oncology, It’s Steady As She Goes

Jun 24 2016

Companion Diagnostics: The Expanding Reach Of Personalized Medicine

Mar 14 2017

BMS's Early Oncology Head On Novel IO Approaches & Disruptions

Jun 05 2017

A Quick Primer On Roche's Immuno-Oncology Assets

Jun 09 2017

Bristol's New Chief Scientific Officer Lists Oncology Priorities, But Little New

Jun 06 2017

Roche "Disappointed" By ASCO Focus, Progressing CEA-CD3 Bispecific

Jun 07 2017

APHINITY Combo Details Contain No Surprise, Puma's Nerlynx May Benefit

Jun 05 2017

Clinical Trial Snapshot 2016: Novartis Leads On Volume, But Novo Nordisk Posts Highest Success Rate

May 30 2017

Roche's Oncology Strategy: The Long Game Comes Into Focus

Jun 15 2015

Beyond PD-1: Roche Maps Further Checkpoints On Cancer Immune Cycle

Jun 15 2015

Q&A: Roche's Dan Chen Talks Immuno-Oncology Combinations

Jun 20 2016

Related Companies

Roche Holding AG

Bristol Myers Squibb Company

Merck & Co., Inc.

Genentech, Inc.

AstraZeneca PLC

Ventana Medical Systems, Inc.

Foundation Medicine, Inc.

Additional Topics

Market Intelligence ImmunoOncology Clinical Trials Companies Strategy Research & Development Cancer BioPharmaceutical

More from Immuno-oncology

More from Anticancer

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window